Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, focuses on the development of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing an unmodified phytocannabinoid combination for orphan indications in neuropathic pain. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.